Morepen Laboratories share news and announcements
NSE: MOREPENLABBSE: 500288Pharmaceuticals & BiotechnologySmall Cap
Last close ₹123.54up ₹5.87 (4.99%)BSE ₹123.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹117.67.
52-week range of traded prices to 23 Oct 2026
₹33.05Low, 30 Mar 2026₹150.70High, 7 Oct 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 27 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹6,769 Cr1,108th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 4 Aug 2026
- 48.2
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹26 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 59.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 5.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.16%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 4 Aug 2026
- 11.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹26 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 9.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 4 Aug 2026
- 10.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.16
- Volume, NSEVolume. Shares traded on the last trading day.
- 50,63,581
Morepen Laboratories results
69 filed, newest first. Page 2 of 2.
Nov 2014
Aug 2014
May 2014
Feb 2014
Nov 2013
Aug 2013
May 2013
Feb 2013
Nov 2012
Aug 2012
May 2012
Feb 2012
Nov 2011
Aug 2011
May 2011
Feb 2011
Apr 2010
30 Apr · Results
Company has decided to submit audited financial results for the entire financial year within 60 days of the end of the financial year instead to submit un-audited financial results along with the limited review report within 45 days.
Apr 2009
21 Apr · Results
Company has proposed to file Audited Accounts for the last quarter ended on March 31, 2009. And therefore instead of Un audited Accounts, with Limited Review Report, the Company will provide Audited Accounts for the year along with the Audit Statement for the last quarter, within 3 months of the end of the financial year, as per the listing agreement i.e. by June 30, 2009.
Apr 2008
23 Apr · Results
We shall be submitting and publishing the audited annual financial results within a period of 3 months from the close of the financial year ending as on March 31, 2008.